Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Atacand

Last reviewed on RxList: 7/8/2020
Atacand Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Atacand?

Atacand (candesartan cilexetil) is a selective AT1 subtype angiotensin II receptor antagonist used to treat high blood pressure (hypertension) in adults and children 1 to less than 17 years of age.

What Are Side Effects of Atacand?

Common side effects of Atacand include:

  • runny or stuffy nose,
  • sore throat,
  • cough,
  • back pain,
  • joint pain,
  • stomach pain,
  • diarrhea,
  • headache,
  • dizziness,
  • tired feeling,
  • feeling like you might pass out,
  • chest pain,
  • swelling in your hands or feet,
  • slow heart rate,
  • weak pulse, or
  • tingly feeling.

Tell the doctor immediately if you notice any of these side effects.

Dosage for Atacand

The usual recommended starting dose of Atacand is 16 mg once daily when it is used as monotherapy in patients who are not volume depleted. Atacand can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg.

What Drugs, Substances, or Supplements Interact with Atacand?

Atacand may interact with alcohol, potassium supplements or salt substitutes, diuretics (water pills), lithium; or NSAIDs (non-steroidal anti-inflammatory drugs) Tell your doctor all medications and supplements you use.

Additional Information

Our Atacand Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Heart Disease: Symptoms, Signs, and Causes See Slideshow
Atacand Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • a light-headed feeling, like you might pass out;
  • fast or slow heartbeats;
  • unusual muscle pain or weakness;
  • high potassium level--nausea, weakness, tingly feeling, chest pain, irregular heartbeats, loss of movement; or
  • kidney problems--little or no urination, swelling in your feet or ankles, feeling tired or short of breath.

Common side effects may include:

  • headache, back pain;
  • dizziness; or
  • cold symptoms such as stuffy nose, sneezing, sore throat.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Atacand (Candesartan Cilexetil)

QUESTION

In the U.S., 1 in every 4 deaths is caused by heart disease. See Answer
Atacand Professional Information

SIDE EFFECTS

Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Adult Hypertension

ATACAND has been evaluated for safety in more than 3600 patients/subjects, including more than 3200 patients treated for hypertension. About 600 of these patients were studied for at least 6 months and about 200 for at least 1 year. In general, treatment with ATACAND was well tolerated. The overall incidence of adverse events reported with ATACAND was similar to placebo.

The rate of withdrawals due to adverse events in all trials in patients (7510 total) was 3.3% (i.e., 108 of 3260) of patients treated with ATACAND as monotherapy and 3.5% (i.e., 39 of 1106) of patients treated with placebo. In placebo-controlled trials, discontinuation of therapy due to clinical adverse events occurred in 2.4% (i.e., 57 of 2350) of patients treated with ATACAND and 3.4% (i.e., 35 of 1027) of patients treated with placebo.

The most common reasons for discontinuation of therapy with ATACAND were headache (0.6%) and dizziness (0.3%).

The adverse events that occurred in placebo-controlled clinical trials in at least 1% of patients treated with ATACAND and at a higher incidence in candesartan cilexetil (n = 2350) than placebo (n = 1027) patients included back pain (3% vs. 2%), dizziness (4% vs. 3%), upper respiratory tract infection (6% vs. 4%), pharyngitis (2% vs. 1%), and rhinitis (2% vs. 1%).

Pediatric Hypertension

Among children in clinical studies, 1 in 93 children age 1 to < 6 and 3 in 240 age 6 to < 17 experienced worsening renal disease. The association between candesartan and exacerbation of the underlying condition could not be excluded.

Heart Failure

The adverse event profile of ATACAND in adult heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the CHARM program, comparing ATACAND in total daily doses up to 32 mg once daily (n=3803) with placebo (n=3796), 21.0% of patients discontinued ATACAND for adverse events vs. 16.1% of placebo patients.

Postmarketing Experience

The following adverse reactions were identified during post-approval use of ATACAND. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following have been very rarely reported in post-marketing experience:

Digestive: Abnormal hepatic function and hepatitis.

Hematologic: Neutropenia, leukopenia, and agranulocytosis.

Immunologic: Angioedema.

Metabolic and Nutritional Disorders: Hyperkalemia, hyponatremia.

Respiratory System Disorders: Cough.

Skin and Appendages Disorders: Pruritus, rash and urticaria.

Rare reports of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers.

Read the entire FDA prescribing information for Atacand (Candesartan Cilexetil)

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW